InvestorsHub Logo
icon url

marzan

05/03/20 8:59 PM

#281327 RE: Lykiri #281322

Thanks Lykiri. All Longs must watch this Q&A clip on how subtle he is about DcVaxL as he can't speak up about it as he is on its steering committee. This doc is big really big in the field of GBM looking at the vast experience comes out in his presentation. Amazing people are there in the world keeps it going. It is all evident all along his presentation that DcVaxL is going to get approved in the next 6 months that he insists saving the resected brain tumor banking it for possible all kinds of vaccine therapy, I guess he is restricted to say L therapy.
icon url

extrooper

05/03/20 9:33 PM

#281329 RE: Lykiri #281322

Interesting insight into clinical
icon url

CherryTree1

05/03/20 9:52 PM

#281332 RE: Lykiri #281322

Muy Interesante - Thanks for sharing Lykiri
icon url

Doc logic

05/03/20 11:27 PM

#281338 RE: Lykiri #281322

Lykiri,

Supratotal resection and immunotherapy. Isn't that what Dr. Linda Liau said years ago about trying to get below the 10,000 tumor cell mark for DC vaccines? Oh yeah, that and that (methylated) mesenchymal responds very well to treatment. Best wishes.
icon url

sukus

05/03/20 11:39 PM

#281339 RE: Lykiri #281322

Excellent information Lykiri.
icon url

eagle8

05/04/20 9:05 AM

#281367 RE: Lykiri #281322


Thank you Lykiri.

GLTU
icon url

NeWBrO

05/04/20 10:50 AM

#281380 RE: Lykiri #281322

From ASCO 2019 : Although not specifically mentioned, seems like DCVax-L should be the leader in below generic category ( PIII complete ... ) :

" The most exciting vaccines are the ones that sequence a tumor to look
for neoantigens and develop personalized vaccines against neoantigens "

Dr. Patrick Wen

https://user-5j6avhy.cld.bz/PracticeUpdate-Oncology-Best-of-2019/14/